Zetia and Bupropion Interaction: What Patients and Clinicians Need to Know

How Each Drug Works: A Quick Metabolic Overview

Before examining whether ezetimibe and bupropion interact, you need to understand how each drug is handled by the body. The two drugs travel almost entirely separate metabolic routes, which is why most clinical pharmacists rate this pairing as having no significant pharmacokinetic interaction.

Ezetimibe Metabolism

Ezetimibe is absorbed in the small intestine, where it inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter and blocks dietary and biliary cholesterol absorption. After absorption, it undergoes rapid conjugation via UGT1A1 and UGT1A3 glucuronidation in the intestinal wall and liver, producing the active glucuronide metabolite ezetimibe-glucuronide [1]. This glucuronide form reaches roughly 3 to 4 times higher plasma concentrations than the parent drug and accounts for the majority of pharmacological activity [1].

Ezetimibe does not meaningfully inhibit or induce CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations, as confirmed in the Zetia prescribing information reviewed by the FDA [2]. This is the single most important metabolic fact when assessing interactions with drugs that depend on CYP pathways.

Bupropion Metabolism

Bupropion is primarily metabolized by CYP2B6 to hydroxybupropion, its most abundant and pharmacologically active metabolite [3]. Secondary reductions produce threohydrobupropion and erythrohydrobupropion via carbonyl reductases. Bupropion and hydroxybupropion are moderate-to-strong inhibitors of CYP2D6, which is clinically significant for drugs whose clearance depends on that enzyme [3].

The FDA label for Wellbutrin XL explicitly states that co-administration with CYP2D6 substrates may require dose reduction of those substrates [4]. Ezetimibe is not a CYP2D6 substrate, so this warning does not apply to it.

The Direct Pharmacokinetic Interaction: What the Evidence Shows

The short answer: no direct pharmacokinetic interaction between ezetimibe and bupropion has been identified in the published literature or in the FDA labeling for either drug as of this writing.

Why No CYP Overlap Matters

Bupropion's most consequential interaction liability comes from CYP2D6 inhibition. Drugs that rely on CYP2D6 for their primary clearance, such as codeine, tramadol, the tricyclic antidepressants, and tamoxifen, show measurable plasma-level changes when bupropion is added [4]. Ezetimibe bypasses this enzyme entirely, running through UGT glucuronidation instead [1].

A 2006 review in the Journal of Clinical Pharmacology characterized ezetimibe's interaction profile as narrow compared with statins, noting no clinically relevant interactions with CYP-mediated pathways in any of the formal drug-interaction studies conducted during the NDA filing [5].

P-glycoprotein Considerations

Both drugs interact to some degree with intestinal transporters. Ezetimibe is a substrate of P-glycoprotein (P-gp) and OATP1B1/1B3 transporters [1]. Bupropion has weak P-gp inhibitory activity in vitro, but human pharmacokinetic data have not demonstrated a clinically meaningful change in ezetimibe bioavailability attributable to bupropion-driven P-gp inhibition [3]. The protein-binding difference (ezetimibe ~99.7%, bupropion ~84%) also does not produce a displacement interaction of clinical relevance, because highly protein-bound drugs with large volumes of distribution rarely show meaningful displacement effects in practice [6].

Bupropion's Seizure Risk: The Pharmacodynamic Concern Worth Flagging

Even when two drugs lack a pharmacokinetic interaction, pharmacodynamic concerns can still matter. Bupropion lowers the seizure threshold in a dose-dependent manner. This is not a theoretical footnote; it is listed as a boxed warning in the Wellbutrin and Zyban prescribing information [4].

Dose and Seizure Incidence

At doses up to 300 mg/day (immediate-release formulation), the seizure incidence is approximately 0.1%. Above 450 mg/day, the rate rises to approximately 0.4%, representing a roughly fourfold increase [4]. The FDA-approved maximum daily dose for any bupropion formulation is 450 mg (immediate-release or sustained-release) or 522 mg for the extended-release formulation used in smoking cessation (Aplenzin 522 mg).

The Wellbutrin XL label states directly: "The risk of seizure is dose-related. The seizure incidence associated with WELLBUTRIN XL has not been formally evaluated in clinical trials; however, the risk of seizure with bupropion HCl immediate-release (IR) at doses up to 300 mg per day is approximately 0.1%." [4]

What This Means for Patients Taking Ezetimibe

Ezetimibe does not lower the seizure threshold, has no CNS activity, and does not affect the pharmacokinetics of bupropion or its metabolites. Adding Zetia to a bupropion regimen does not, by any established mechanism, increase the seizure risk beyond what bupropion alone confers [2]. Clinicians should document seizure history, alcohol use patterns, and co-prescribing of other seizure-threshold-lowering agents regardless of whether ezetimibe is on the medication list.

Clinical Significance Rating and Guideline Positioning

Standard drug-interaction databases, including those maintained by the FDA's Drug Interaction Database Program, assign interaction pairs a severity rating based on mechanistic plausibility, pharmacokinetic data, and documented clinical events. The ezetimibe-bupropion pair has no established interaction rating in the FDA's labeling for either drug [2, 4], and no case reports in PubMed document an adverse event attributed to co-administration as of the date of this review.

How Interaction Severity Is Graded

The Lexicomp and Micromedex systems both use a five-tier classification (contraindicated, major, moderate, minor, unknown). Pairs with no mechanistic basis and no clinical reports generally fall into "minor" or "no interaction known." Clinicians consulting these tools for ezetimibe-bupropion will typically see a "no known interaction" or low-risk flag [6].

ACC/AHA Lipid Guideline Context

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends ezetimibe as a second-line agent added to maximally tolerated statin therapy in patients who need further LDL-C reduction [7]. Patients on bupropion for depression or smoking cessation who also have atherosclerotic cardiovascular disease (ASCVD) are a common clinical overlap group, because smoking cessation itself reduces ASCVD risk and bupropion is a guideline-supported cessation aid. The 2018 guideline does not list bupropion as a drug requiring special interaction management with lipid-lowering agents [7].

Evidence from Key Ezetimibe Trials

Understanding ezetimibe's efficacy and safety record helps contextualize why it is broadly co-prescribed with agents from unrelated drug classes.

IMPROVE-IT Trial

The IMPROVE-IT trial (N=18,144) evaluated the addition of ezetimibe 10 mg to simvastatin 40 mg versus simvastatin 40 mg alone in patients with recent acute coronary syndrome [8]. The ezetimibe group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-alone group. The 7-year cardiovascular event rate was 32.7% in the ezetimibe group versus 34.7% in the monotherapy group (absolute risk reduction 2.0%, hazard ratio 0.936, P<0.001) [8]. The trial recorded no seizure signal attributable to ezetimibe and no interaction-related adverse events involving co-prescribed CNS medications.

SHARP Trial

SHARP (N=9,270) tested simvastatin 20 mg plus ezetimibe 10 mg against placebo in patients with chronic kidney disease [9]. The combination reduced major atherosclerotic events by 17% (rate ratio 0.83, 95% CI 0.74 to 0.94, P<0.001) [9]. Again, the safety database showed no interaction signals between ezetimibe and any co-prescribed neuropsychiatric agents.

Ezetimibe's Actual Clinically Significant Interactions

To give this article honest clinical utility, the interactions that genuinely matter for ezetimibe deserve specific attention, even though bupropion is not among them.

Cyclosporine

Co-administration of cyclosporine (an OATP1B1/P-gp inhibitor) with ezetimibe approximately doubles ezetimibe-glucuronide area under the curve (AUC) [2]. The Zetia label recommends caution and monitoring when these two drugs are used together [2].

Cholestyramine and Other Bile Acid Sequestrants

Cholestyramine reduces ezetimibe AUC by approximately 55% when co-administered [2]. The practical solution is to take ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant [2].

Fibrates

Co-administration with fenofibrate increases ezetimibe AUC by approximately 1.5-fold. Co-administration with gemfibrozil increases ezetimibe-glucuronide AUC by approximately 1.7-fold [2]. Neither combination is contraindicated, but cholecystitis risk from fibrates warrants monitoring [2].

Statins

Ezetimibe is frequently prescribed with statins and does not alter statin pharmacokinetics to a clinically meaningful degree. Rosuvastatin AUC increases modestly (~20%) when combined with ezetimibe, but this falls within the normal variability range and no dose adjustment is required [2].

Bupropion's Clinically Significant Interactions: For Contrast

Bupropion's interaction list is meaningfully longer than ezetimibe's, driven by its CYP2D6 inhibition.

CYP2D6 Substrates

Drugs with narrow therapeutic windows that depend on CYP2D6 include nortriptyline, desipramine, imipramine, haloperidol, risperidone, thioridazine, metoprolol, flecainide, and propafenone [4]. Co-prescribing bupropion with these agents may require 50% dose reductions of the CYP2D6 substrate, per FDA labeling [4]. Ezetimibe is not on this list.

MAOIs

Concurrent use of bupropion with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of hypertensive crisis [4]. At least 14 days must separate MAOI discontinuation and bupropion initiation [4].

Dopaminergic Agents

Levodopa and amantadine may produce additive dopaminergic adverse effects (nausea, restlessness, tremor) when combined with bupropion [4]. Dose titration should be gradual when adding either agent.

A Practical Clinical Decision Framework for Co-Prescribing

When a patient presents on both ezetimibe and bupropion, a structured review takes less than three minutes and covers the meaningful risks.

Step 1: Confirm the Bupropion Dose and Formulation

Document whether the patient is on immediate-release (maximum 150 mg three times daily), sustained-release (maximum 200 mg twice daily), or extended-release (maximum 450 mg once daily for depression, 522 mg for smoking cessation). Doses above the approved ceiling sharply increase seizure risk, and that risk is independent of ezetimibe [4].

Step 2: Screen for Seizure Risk Modifiers

Ask about: personal or family history of seizures, eating disorders (bulimia and anorexia independently lower seizure threshold), heavy alcohol use or recent discontinuation, concomitant use of other seizure-threshold-lowering agents (antipsychotics, systemic corticosteroids, theophylline), and head trauma history. None of these factors involve ezetimibe, but they must be documented before bupropion can be safely continued [4].

Step 3: Review the Full Lipid-Lowering Regimen

If the patient is also on cyclosporine (e.g., post-transplant), the ezetimibe dose and AUC require additional attention. If bile acid sequestrants are present, confirm the administration-timing separation. Bupropion does not affect this stagger.

Step 4: Confirm No Interacting Agents Were Missed

The most common clinical error is not the ezetimibe-bupropion pair but the simultaneous presence of a CYP2D6-sensitive drug with bupropion. Run a full reconciliation against the CYP2D6 substrate list before signing off.

Step 5: Patient Counseling Points

Tell the patient to avoid alcohol while on bupropion, report any unusual twitching, staring episodes, or muscle jerking immediately, and take ezetimibe at a consistent time relative to any bile acid sequestrant. Ezetimibe can be taken at any time of day, with or without food, regardless of bupropion dosing schedule [2].

Monitoring Parameters When Both Drugs Are Prescribed

Standard lipid monitoring for ezetimibe: a fasting lipid panel 4 to 12 weeks after initiation or dose change, then every 3 to 12 months per the 2018 ACC/AHA guideline [7]. Liver function testing is not routinely required for ezetimibe monotherapy, though it is prudent when ezetimibe is added to a statin [7].

Standard monitoring for bupropion: blood pressure at baseline and after dose changes (bupropion produces modest mean increases of 1 to 2 mmHg systolic in most patients) [4]; mood and suicidality assessments per the FDA black-box warning for antidepressants in patients aged <25 years; and periodic review of seizure risk factors.

No additional monitoring is required because of the co-prescription of these two specific drugs together, beyond what each drug independently requires.

Special Populations

Renal Impairment

Ezetimibe dose adjustment is not required in mild-to-moderate renal impairment. Bupropion requires caution in severe renal impairment (GFR <30 mL/min) because hydroxybupropion accumulates; the FDA label recommends the lowest effective dose and increased monitoring [4].

Hepatic Impairment

Ezetimibe is not recommended in moderate-to-severe hepatic impairment (Child-Pugh B or C) due to unknown exposure levels [2]. Bupropion is also used with caution in severe hepatic impairment; the maximum dose in severe cirrhosis is 75 mg once daily for immediate-release [4].

Pregnancy and Lactation

Ezetimibe is contraindicated in pregnancy (Pregnancy Category X when used with statins; avoid as monotherapy as well given lack of safety data) [2]. Bupropion is Pregnancy Category C; data from the Bupropion Pregnancy Registry showed no consistent pattern of major malformations above background rates across approximately 1,600 prospectively enrolled pregnancies, but the registry was not powered to detect small effects [10]. Both drugs are excreted in breast milk; the clinical decision to breastfeed while on either agent should involve a risk-benefit discussion.

Pediatric and Adolescent Patients

Neither drug is approved for pediatric lipid lowering (ezetimibe) or depression (bupropion) in patients <18 years. The FDA black-box warning for increased suicidality with antidepressants applies specifically to patients <25 years [4].